RENAL CELL CARCINOMA

This study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma that had spread or come back after treatment. The goal was to find a safe dose and see if the drug could shrink tumors. The trial was stopped early, so re…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in adults with melanoma or kidney cancer that had spread to the brain. Participants had already received anti-PD-1/PD-L1 treatments. The goal was to see if the drug combo could shrink brain tumors. The st…

This early-phase study tested a new drug (PF-07826390) alone or with another drug (sasanlimab) in 10 people with advanced solid tumors like lung, colon, or kidney cancer. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This study tested a new drug called OC-001, either by itself or combined with avelumab (an immunotherapy), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The trial was stopped early, and only 73 people were e…

This early-phase study tested a new drug called SO-C101, alone or with pembrolizumab, in 115 people with advanced solid tumors (like lung, kidney, or skin cancer) that stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study …

This early-stage study tested a new drug, PF-07820435, alone or with another drug (sasanlimab), in 9 people with advanced solid tumors like lung, skin, and kidney cancers. The main goal was to check safety and find the right dose. The study was stopped early, so results are limit…

This study tested a new drug, HFB301001, in 31 adults with advanced cancers like sarcoma and melanoma. The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.

This trial tested an oral drug called NKT2152 in 120 people with advanced clear cell kidney cancer that had worsened after other treatments. The goal was to find the safest dose and see if it could shrink tumors. The study was stopped early, but results may help guide future trea…

This early-phase study tested a new treatment called ITIL-306 for people with advanced ovarian, lung, or kidney cancers that stopped responding to standard therapies. ITIL-306 uses a patient's own immune cells, modified to better recognize and attack tumors. The study was termina…

This early-phase study tested a new medicine called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, skin, head and neck, or colorectal cancer. The goal was to check safety and how the body handles the dr…

This study looked at whether a special type of MRI called Arterial Spin Labeling can measure blood flow changes in kidney cancer tumors as early as one to two weeks after starting treatment. Six people with advanced kidney cancer took part. The goal was to see if this scan could …